Blog Entry Correction
Yesterday’s blog post about Harvoni passing its Common Drug Review this week stated that one of the Canadian Drug Expert Committee’s recommendations was that liver fibrosis should be “stage 2 or lower“. The post should have read “Liver fibrosis stage ≥ 2” or “Liver fibrosis stage 2 or higher.”
I apologize for the typo. I may have been a wee excited about the Harvoni news.
Harvoni, created by Gilead Sciences, passed its Common Drug Review this week with the Canadian Drug Expert Committee (CDEC)’s Final Recommendation. The CDEC’s Final Recommendation advocates that Harvoni, ledipasvir/sofosbuvir, be listed for the treatment of chronic hepatitis C virus (CHC) genotype 1 infection in adults. It recommended 3 conditions for this.
The 3 conditions recommended by the Canadian Drug Expert Committee were:
- Liver fibrosis be at stage 2 or higher
- Treatment should be initiated by physicians experienced with treating chronic hep C
- A substantial reduction in price
Reasons for the Recommendations were:
The CDEC’s report also covered such information as the treatment’s background, efficacy, side effects, and cost and cost-effectiveness.
The website for BC’s PharmaCare now lists Harvoni’s Drug Review Start Date as March 18th, 2015.
When I read the report, I found an interesting note under “Other Discussion Points”. It said that although the ION trials didn’t look at patients coinfected with HCV and HIV, the committee did and cited that ERADICATE, a recently completed trial, demonstrated similar SVR12 rates (98%) in patients coinfected with HCV and HIV to those reported in the three ION trials.